Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab induction and chemoradiotherapy in ESCC
NCT06420908Phase 2Withdrawn
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Fourth Hospital of Hebei Medical University. Planned start May 2024; status: withdrawn.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06420908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06420908.